Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Thiazides in kidney transplant recipients: skin in the game

Nature Reviews Nephrology (2024)Cite this article

Subjects

Clinical trial data suggest that thiazides and thiazide-like drugs could be beneficial for blood-pressure lowering in patients with severe chronic kidney disease. However, prolonged exposure to these photosensitizing drugs could translate into increased risk of squamous cell carcinoma and post-transplant diabetes in the already extremely vulnerable kidney transplant population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The role of thiazides in the development of squamous cell carcinoma after transplantation.

References

  1. Agarwal, R. et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N. Engl. J. Med. 385, 2507–2519 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Georgianos, P. I. & Agarwal, R. Hypertension in chronic kidney disease-treatment standard 2023. Nephrol. Dial. Transplant. 38, 2694–2703 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Moes, A. D., Hesselink, D. A., van den Meiracker, A. H., Zietse, R. & Hoorn, E. J. Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: a randomized crossover trial. Am. J. Kidney Dis. 69, 796–804 (2017).

    Article  CAS  PubMed  Google Scholar 

  4. Taber, D. J. et al. Are thiazide diuretics safe and effective antihypertensive therapy in kidney transplant recipients? Am. J. Nephrol. 38, 285–291 (2013).

    Article  CAS  PubMed  Google Scholar 

  5. Kramers, B. J. et al. Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin v2 receptor antagonist in ADPKD: a randomized crossover trial. Clin. J. Am. Soc. Nephrol. 17, 507–517 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shao, S. C. et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med. 20, 228 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  7. VanWormer, J. J., Abokede, E. B. & Berg, R. L. Hydrochlorothiazide use, sun exposure, and risk of keratinocyte cancer. BMC Public Health 22, 1282 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Fuhrmann, J. D. et al. Cancer among kidney transplant recipients >20 years after transplantation: post-transplant lymphoproliferative disorder remains the most common cancer type in the ultra long-term. Clin. Kidney J. 15, 1152–1159 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Letellier, T. et al. Association between use of hydrochlorothiazide and risk of keratinocyte cancers in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 15, 1804–1813 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bretagnol, A. et al. Autosomal dominant polycystic kidney disease: risk factor for nonmelanoma skin cancer following kidney transplantation. Transpl. Int. 23, 878–886 (2010).

    PubMed  Google Scholar 

  11. Nazarzadeh, M. et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet 398, 1803–1810 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kucharczyk, P. et al. Thiazides attenuate insulin secretion through inhibition of mitochondrial carbonic anhydrase 5b in β-islet cells in mice. J. Am. Soc. Nephrol. 34, 1179–1190 (2023).

    Article  PubMed  Google Scholar 

  13. Sokooti, S. et al. Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients. Nephrol. Dial. Transplant. 37, 1375–1383 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. de Mattos, A. M. et al. Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int. 67, 714–720 (2005).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal Division, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

    Steven Van Laecke

Authors
  1. Steven Van Laecke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Van Laecke.

Ethics declarations

Competing interests

The author declares no competing interests.

Peer review

Peer review information

Nature Reviews Nephrology thanks Peter Conlan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Van Laecke, S. Thiazides in kidney transplant recipients: skin in the game. Nat Rev Nephrol (2024). https://doi.org/10.1038/s41581-024-00839-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41581-024-00839-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing